ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.320,96
0,33%
S&P 500
5.631,22
0,28%
US Dollar vs BRL
5,4486
0,01%
Bitcoin
64.733,91
-0,18%
Brent Oil
84,085
-0,30%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Tango Therapeutics Inc (TNGX)

  7. Tango Therapeutics Inc (TNGX) Notícias

TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TNGX
DataHoraFonteTítuloCódigoCompanhia
24/07/202308:00GlobeNewswire Inc.Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant CancersNASDAQ:TNGXTango Therapeutics Inc
01/06/202308:00GlobeNewswire Inc.Tango Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:TNGXTango Therapeutics Inc
09/05/202308:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TNGXTango Therapeutics Inc
09/05/202308:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TNGXTango Therapeutics Inc
09/05/202308:00GlobeNewswire Inc.Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
24/04/202317:48Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:TNGXTango Therapeutics Inc
24/04/202317:41Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TNGXTango Therapeutics Inc
24/04/202317:32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TNGXTango Therapeutics Inc
18/04/202317:30GlobeNewswire Inc.Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
03/04/202308:00GlobeNewswire Inc.Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant CancersNASDAQ:TNGXTango Therapeutics Inc
27/03/202308:00GlobeNewswire Inc.Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
14/03/202321:11GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
11/03/202300:15GlobeNewswire Inc.Tango Therapeutics Announces Limited Exposure to Silicon Valley BankNASDAQ:TNGXTango Therapeutics Inc
06/03/202309:00GlobeNewswire Inc.Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
02/03/202318:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TNGXTango Therapeutics Inc
02/03/202318:07Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:TNGXTango Therapeutics Inc
28/02/202309:00GlobeNewswire Inc.Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and DevelopmentNASDAQ:TNGXTango Therapeutics Inc
14/02/202317:03Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TNGXTango Therapeutics Inc
07/02/202318:07Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:TNGXTango Therapeutics Inc
25/01/202309:00GlobeNewswire Inc.Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business UpdatesNASDAQ:TNGXTango Therapeutics Inc
15/12/202209:00GlobeNewswire Inc.HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of DirectorsNASDAQ:TNGXTango Therapeutics Inc
18/11/202208:25TipRanksH.C. Wainwright Sticks to Their Buy Rating for Tango Therapeutics (TNGX)NASDAQ:TNGXTango Therapeutics Inc
14/11/202200:56TipRanksTango Therapeutics (TNGX) Gets a Buy from SVB SecuritiesNASDAQ:TNGXTango Therapeutics Inc
10/11/202209:00GlobeNewswire Inc.Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
19/10/202208:00GlobeNewswire Inc.Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsNASDAQ:TNGXTango Therapeutics Inc
05/10/202209:10GlobeNewswire Inc.Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
06/09/202208:00GlobeNewswire Inc.Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:TNGXTango Therapeutics Inc
01/09/202217:14Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:TNGXTango Therapeutics Inc
10/08/202208:00GlobeNewswire Inc.Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
02/08/202208:00GlobeNewswire Inc.Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TNGX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
INBR32
Inter &
BOV
GFSA3
GAFISA ON
BOV
AZEV4
AZEVEDO PN
BOV
AMER3
Americanas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados